A role for tumor suppressor protein p53 in the fidelity of DNA synthesis and resistance towards nucleoside analogs

Current Cancer Therapy Reviews

Volumn 2, Issue 3, 2006, Pages 231-241

  Bakhanashvili, Mary ^a,b   Rahav, Galia ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

3 5 exonuclease activity; Genomic stability; Nucleoside analogs; p53

Indexed keywords

CYTARABINE; DNA; DNA DIRECTED DNA POLYMERASE ALPHA; DNA POLYMERASE; FLUDARABINE; GEMCITABINE; NUCLEOSIDE ANALOG; PHOSPHODIESTERASE I; PROTEIN P53; RNA DIRECTED DNA POLYMERASE; SPLEEN EXONUCLEASE; ZALCITABINE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BASE MISPAIRING; BREAST CANCER; CANCER RESISTANCE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COLON CANCER; CYTOPLASM; CYTOTOXICITY; DNA REPLICATION; DNA SYNTHESIS; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NEUROBLASTOMA; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; VIRUS INHIBITION;

EID: 33746951385     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339406777934672     Document Type: Article

References (81)

1. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999; 274: 36031-4.
2. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-26.
3. Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmuller L, Deppert W. Maintenance of genomic integrity by p53: complementary roles for activated p53. Oncogene 1999; 18: 7708-17.
4. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. In Molecular genetics of cancer (Cowell, J.K., ed.), 1995; pp135-78, Bios Scientific, Oxford, UK.
5. Kastan MB, Onyekwere O, Sidransky D,Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
6. Nelson W, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815-23.
7. Graeber T, Peterson J, Tsai M, Monica K, Fornace AJ, Giaccia A. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6264-77.
8. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996; 10: 934-47.
9. Oren M, Maltzman W, Levine AJ. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1981; 1: 101-10.
10. Genini D, Sheeter D, Rought S, et al. HIV induces lymphocyte apoptosis by a p53-initiated, mitochondrial-mediated mechanism. FASEB J 2001; 15: 5-6.
11. Cox LS, Hupp T, Midgley CA, Lane DP. A direct effect of activated human p53 on DNA replication. EMBO J 1995; 14: 2099-105.
12. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
13. Hwang BJ, Ford J.M, Hanawalt PC, Chu G. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 1999; 96: 424-8.
14. Dudenhoffer C, Rohaly G, Will K, Deppert W, Wiesmullar L. 1998 Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination. Mol Cell Biol 1995; 18: 5332-42.
15. Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 1999; 450: 197-204.
16. Zhou J, Ahn J, Wilson SH, Prives C. A role for p53 in base excision repair. EMBO J 2001; 20: 914-23.
17. Offer H, Milyavsky M, Erez N, et al. Structural and functional involvement of p53 in BER in vitro and in vivo. Oncogene 2001; 20: 581-9.
18. Li R, Botchan MR The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication. Cell 1993; 73: 1207-21
19. Janus F, Albrechtsen N, Domreiter L Wiesmuller L, Grosse F, Deppert W. The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 1999; 55: 12-27.
20. Blander G, Kipnis J, Leal JFM, Yu C-E, Schellenberg GD, Oren M. Physical and functional interaction between p53 and the Werner's syndrome protein. J Biol Chem 1999; 274: 29463-9.
21. Cannon JV, Lane DP. P53 and DNA polymerase compete for binding to SV40 antigen. Nature 1987; 329: 456-8.
22. Huang P. Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein. Oncogene 1998; 17: 261-70.
23. Miller SD, Farmer G, Prives C. p53 inhibits DNA replication in vitro in a DNA-binding-dependent manner. Mol Cell Biol 1995; 15: 6554-60.
24. Staib C, Pesch J, Gerwig R, et al. p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T-antigen. Virology 1996; 219: 237-46.
25. Kern SE, Kinzler KW, Baker SJ, et al. Mutant p53 binds DNA abnormally. Oncogene 1991; 6: 131-6.
26. Steinmeyer K, Deppert W. DNA binding properties of murine p53. Oncogene 1988; 3: 501-7.
27. Bakalkin G, Yakovleva T, Selivanova G, et al. P53 binds single-stranded DNA endsand catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci USA 1994; 91: 413-7.
28. Oberosler P, Hloch P, Rammsperger U, Stahl H. p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J 1993; 12: 2389-96.
29. Lee S, Elenbaas B, Levine A, Griffith J. p53 and its 14kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 1995; 81: 1013-20.
30. El-Deiry W, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of consensus binding site for p53. Nat Genet 1992; 1: 45-9.
31. Foord O, Navot N, Rotter V. Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein. Molec Cell Biol 1993; 13: 1378-84.
32. Mummenbrauer T, Janus F, Muller B, Wiesmuller L, Deppert W, Gross F. p53 protein exhibits 3′-to 5′ exonuclease activity. Cell 1996; 85: 1089-99.
33. Echols H, Goodman MF. Fidelity mechanisms in DNA replication. Ann Rev Biochem 1991; 60: 477-511.
34. Jackson AL, Loeb LA. The mutation rate and cancer. Genetics 1998; 148: 1483-90.
35. Shevelev IV, Hubscher U. The 3′ → 5′ exonucleases. Nat Rev 2002; 3: 1-12.
36. Hubscher U, Maga G, Spadari S. Eukaryotic DNA polymerases. Annu Rev Biochem 2002; 71: 133-63.
37. Bakhanashvili M, Hizi A. Fidelity of the reverse transcriptase of human immunodeficiency virus type. FEBS Lett 1992; 306: 151-6.
38. Bakhanashvili M, Hizi A. Fidelity of DNA synthesis exhibited in vitro by the reverse transcriptase of the lentivirus equine infectious anemia virus. Biochemistry 1993; 32: 7559-7567.
39. Joyce C.M. How DNA travels between the separate polymerase and 3′ → 5′ exonuclease sites of DNA polymerase I (Klenow fragment). J Biol Chem 1989; 264: 858-66.
40. Brutlag D, Kornberg A. Enzymatic synthesis of deoxyribonucleic acid 36. A proofreading function for the 3′ leads to 5′ exonuclease activity in deoxyribonucleic acid polymerases. J Biol Chem 1972; 247: 241-8.
41. Perrino FW, Loeb LA. Hydrolysis of 3′ -terminal mispairs in vitro by the 3′ → 5′ exonuclease of DNA polymerase δ permits subsequent extension by DNA polymerase α. Biochemistry 1990; 29: 5226-31.
42. Maki H, Kornberg A. Proofreading by DNA polymerase III of Escherichia coli depends on cooperative interaction of the polymerase and exonuclease subunits. Proc Natl Acad Sci USA 1987; 84: 4389-92.
43. Janus F, Albrechtsen N, Knippschild U, Wiesmuller L, Grosse F, Deppert W. Different regulation of the p53 core domain activities 3′ to 5′ exonuclease and sequence-specific DNA binding. Mol Cell Biol 1999; 19: 2155-68.
44. Skalski V, Lin Z, Choi BY, Brown KR. Substrate specificity of the p53-associated 3′ → 5′ exonuclease. Oncogene 2000; 19: 3321-9.
45. Bakhanashvili M. Exonucleolytic proofreading by p53 protein. Eur J Biochem 2001; 268: 2047-54.
46. Bakhanashvili M. p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. Oncogene 2001; 20: 7635-44.
47. Melle C, Nasheuer H. Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase α-primase. Nucleic Acids Res 2002; 30: 1493-9.
48. Ballal K, Zhang W, Mukhopadyay T, Huang P. Suppression of mismatched mutation by p53: a mechanism guarding genomic integrity. J Mol Med 2002; 80: 25-32.
49. Peng H, Chen G, Du M, Singh N, Isaacson PG, Pan L. Replication error phenotype and p53 gene mutation in lymphoma of mucosa associated lymphoid tissue. Am J Pathol 1996; 148: 643-8.
50. Stoler DL, Chen N, Basik M, et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 1999; 96: 15121-6.
51. Stenmark-Askmalm M, Stal O, Sullivan S, et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 1994; 30A: 175-80.
52. Moll UM, LaOuglia M, Benard, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995; 92: 4407-11.
53. Bosari S, Viale G, Roncalli M, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995; 147: 790-8.
54. Sun XF, Cartensen J.M, Zhang H, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992; 340: 1369-73.
55. Lilling G, Nordenberg J, Rotter V, Goldfinger N, Peller S, Sidi Y. Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. Cancer Invest 2002; 20: 509-17.
56. Lilling G, Novitsky E, Sidi Y, Bakhanashvili M. p53-associated 3′ → 5′ exonuclease activity in nuclear and cytoplasmic compartments of cells. Oncogene 2003; 22: 233-45.
57. Meek DW. New developments in the multi-site phosphorylation and integration of stress signalling at p53. Int J Radiat Biol 1998; 74: 729-37.
58. Milner J, Watson JV. Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene 1990; 5: 1683-90.
59. Sabapathy K, Klemm M, Jaenisch R, Wagner EF. Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J 1997; 16: 6217-29.
60. Gaitonde SV, Riley JR, Qiao D, Martinez JD. Conformational phenotype of p53 is linked to nuclear translocation. Oncogene 2000; 19: 4042-49.
61. Okorokov A, Rubbi CP, Metcalfe S, Milner J. The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage. Oncogene 2002; 21: 356-67.
62. Kunkel T. Exonucleolytic proofreading. Cell 1988; 53: 837-40.
63. Mendelman LV, Petruska JS, Goodman MF. Base mispair extension kinetics. Comparison of DNA polymerase alpha and reverse transcriptase. J Biol Chem 1990; 265: 2338-46.
64. Perrino FW, Loeb LA. Proofreading by the ε subunit of Escherichia coli DNA polymerase III increases the fidelity of calf thymus DNA polymerase α. Proc Natl Acad Sci USA 1989; 86: 3085-88.
65. Perrino FW, Preston BD, Sandell LL, Loeb LA. Extension of mismatched 3′ termini of DNA is a major determinant of the infidelity of human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA 1989; 86: 8343-47.
66. Bakhanashvili M, Novitsky E, Lilling G, Rahav G. p53 in cytoplasm may enhance the accuracy of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. Oncogene 2004; 23: 6890-9.
67. Sloane DL, Goodman MF, Echols H. The fidelity of base selection by the polymerase subunit of DNA polymerase III holoenzyme. Nucleic Acid Res 1988 16, 6465-75.
68. Goodman MF, Fygenson DK. Genetics 1998; 148:1475-82.
69. Keating MJ. In: Nucleoside Analogs in Cancer Therapy. Cheson BD. Keating, and Plunkett W (eds). Marcel Dekker, Inc., New York, 1997; pp 201-226.
70. Sluis-Cremer N, Arion D, Parniak MA. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol Life Sci 2000; 57: 1408-22.
71. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36: 181-8.
72. Bakhanashvili M, Novitsky E, Rubinstein E, Levy I, Rahav G. Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemotherapy 2005; 49: 1576-9.
73. Zhou Y, Achanta G, Pelicano H, Gadhi V, Plunkett W, Huang P. Action of (E)-2′- Deoxy-2′-(fluoromethylene) cytidine on DNA metabolism: incorporation, excision and cellular response. Mol Pharm 2002; 61: 222-9.
74. Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W, Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med 2000; 5: 597-604.
75. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 2001; 61: 8723-9.
76. Merlin T, Brandner G, Hess RD. Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs. Int J Oncol 1998; 13: 1007-6.
77. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002; 97: 439-45.
78. Havre PA, Yuan JL, Hedrick L, Cho KR, Glazer PM. P53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995; 55: 4420-24.
79. Lane DP. Cancer: p53, guardian of the genome. Nature 1992; 358: 15-6.
80. Fontoura BMA, Sorokina EA, David E, Carroll RB. P53 is covalently linked to 5.8S rRNA. Mol Cell Biol 1992; 12: 5145-51.
81. Marechal V, Elenbaas B, Piette J, Nicolas J, Levine AJ. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol 1994; 14: 7414-20.